Cargando…

Profile of the Change in Depression during Proton-Pump Inhibitor Therapy in Patients with Gastroesophageal Reflux Disease: Influence of the Mucosal Break

Given the frequent concomitance between depression and gastroesophageal reflux disease (GERD), it is important to evaluate the change of depression in patients with GERD, especially considering the presence of esophageal mucosal breaks (MB). This study aimed to examine the change in the levels of de...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Chia-Liang, Chen, Chien-Lin, Wen, Shu-Hui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8199631/ https://www.ncbi.nlm.nih.gov/pubmed/34199477 http://dx.doi.org/10.3390/ijerph18115964

Ejemplares similares

Helicobacter pylori, proton pump inhibitors and gastroesophageal reflux disease.
por: Kuipers, E. J., et al.
Publicado: (1999)

Effects of Proton Pump Inhibitors on the Gastrointestinal Microbiota in Gastroesophageal Reflux Disease
por: Shi, Yi-Chao, et al.
Publicado: (2019)

Anti-reflux mucosal ablation (ARMA) as a new treatment for gastroesophageal reflux refractory to proton pump inhibitors: a pilot study
por: Inoue, Haruhiro, et al.
Publicado: (2020)

Proton pump inhibitor-refractory gastroesophageal reflux disease: challenges and solutions
por: Mermelstein, Joseph, et al.
Publicado: (2018)

Comparison of Gastroesophageal Reflux Disease Symptoms and Proton Pump Inhibitor Response Using Gastroesophageal Reflux Disease Impact Scale Questionnaire
por: Jo, So Young, et al.
Publicado: (2013)

Is It Useful to Administer Probiotics Together With Proton Pump Inhibitors in Children With Gastroesophageal Reflux?
por: Belei, Oana, et al.
Publicado: (2018)

Combination Treatment With Proton Pump Inhibitor Plus Prokinetic for Gastroesophageal Reflux Disease
por: Tariq, Muhammad Ali, et al.
Publicado: (2022)

Proton pump inhibitors induced fungal dysbiosis in patients with gastroesophageal reflux disease
por: Shi, Yichao, et al.
Publicado: (2023)

Role of Acid and Weakly Acidic Reflux in Gastroesophageal Reflux Disease Off Proton Pump Inhibitor Therapy
por: Sung, Hea Jung, et al.
Publicado: (2012)

The Influences of Visceral Fat Area on the Sites of Esophageal Mucosal Breaks in Subjects with Gastroesophageal Reflux Diseases
por: Nam, Ji Hyung, et al.
Publicado: (2019)

Complete Resolution of Pseudomalignant Erosion in a Reflux Gastroesophageal Polyp with Proton Pump Inhibitor
por: Nakajima, Takahiko, et al.
Publicado: (2015)

Predictive Factors of Response to Proton Pump Inhibitors in Korean Patients With Gastroesophageal Reflux Disease
por: Kim, Sung Eun, et al.
Publicado: (2015)

Additional Mosapride to Proton Pump Inhibitor for Gastroesophageal Reflux Disease: A Meta-Analysis
por: Nishizawa, Toshihiro, et al.
Publicado: (2020)

Efficacy of Vonoprazan for Gastroesophageal Reflux Symptoms in Patients with Proton Pump Inhibitor-resistant Non-erosive Reflux Disease
por: Niikura, Ryota, et al.
Publicado: (2018)

The Influence of Proton Pump Inhibitors on the Fecal Microbiome of Infants with Gastroesophageal Reflux—A Prospective Longitudinal Interventional Study
por: Castellani, Christoph, et al.
Publicado: (2017)

Eosinophilic esophagitis in patients with typical gastroesophageal reflux disease symptoms refractory to proton pump inhibitor
por: de Sá, Cláudia Cristina, et al.
Publicado: (2011)

Does Helicobacter pylori eradication or proton pump inhibitor use benefit gastroesophageal reflux disease?
por: Sakin, Yusuf Serdar, et al.
Publicado: (2015)

Putting Out the Fire: The Relationship of Pharmacogenetics and Proton Pump Inhibitors for the Treatment of Gastroesophageal Reflux Disease
por: Zheng, Connor L, et al.
Publicado: (2018)

Can Esophageal Baseline Impedance Predict Proton Pump Inhibitor Response in Gastroesophageal Reflux Disease?
por: Jung, Kyoungwon, et al.
Publicado: (2018)

Is the Diagnostic Trial with Proton Pump Inhibitors Reasonable for School Age Children with Gastroesophageal Reflux Symptoms?
por: Yang, Jaeeun, et al.
Publicado: (2019)

Effect of a Preoperative Proton Pump Inhibitor and Gastroesophageal Reflux Disease on Postoperative Nausea and Vomiting
por: Kwon, Young Suk, et al.
Publicado: (2020)

Commentary: The Influence of Proton Pump Inhibitors on the Fecal Microbiome of Infants with Gastroesophageal Reflux-A Prospective Longitudinal Interventional Study
por: Drall, Kelsea M., et al.
Publicado: (2018)

Efficacy of vonoprazan for initial and maintenance therapy in reflux esophagitis, nonerosive esophagitis, and proton pump inhibitor-resistant gastroesophageal reflux disease
por: Gotoh, Yasuhiko, et al.
Publicado: (2020)

Anti-reflux Surgery Versus Proton Pump Inhibitors for Severe Gastroesophageal Reflux Disease: A Cost-Effectiveness Study in Korea
por: Park, Susan, et al.
Publicado: (2020)

Efficacy of proton pump inhibitors and H2 blocker in the treatment of symptomatic gastroesophageal reflux disease in infants
por: Azizollahi, Hamid Reza, et al.
Publicado: (2016)

Phenotypes of Jackhammer esophagus in patients with typical symptoms of gastroesophageal reflux disease responsive to proton pump inhibitors
por: Kristo, Ivan, et al.
Publicado: (2018)

Effects of rikkunshito on quality of life in patients with gastroesophageal reflux disease refractory to proton pump inhibitor therapy
por: Kawai, Takashi, et al.
Publicado: (2017)

Protective Effect of Proton Pump Inhibitor for Survival in Patients with Gastroesophageal Reflux Disease and Idiopathic Pulmonary Fibrosis
por: Lee, Chang Min, et al.
Publicado: (2016)

Is empiric proton pump inhibition in patients with symptoms of extraesophageal gastroesophageal reflux justified?
por: Fossmark, Reidar, et al.
Publicado: (2023)

Randomized Controlled Trial of Anti-reflux Mucosectomy Versus Radiofrequency Energy Delivery for Proton Pump Inhibitor-refractory Gastroesophageal Reflux Disease
por: Wang, Yan, et al.
Publicado: (2023)

Proton pump inhibitors for the treatment of patients with erosive esophagitis and gastroesophageal reflux disease: current evidence and safety of dexlansoprazole
por: Mermelstein, Joseph, et al.
Publicado: (2016)

Factors associated with residual gastroesophageal reflux disease symptoms in patients receiving proton pump inhibitor maintenance therapy
por: Kawara, Fumiaki, et al.
Publicado: (2017)

Relationship between long-term use of proton pump inhibitor (PPI) and hypomagnesemia in patients with gastroesophageal reflux disease
por: Arj, Abbas, et al.
Publicado: (2022)

Do patients with gastroesophageal reflux disease exhibit compromised bone quality prior to proton pump inhibitor therapy?
por: Aasarød, Kristin M., et al.
Publicado: (2021)

Effects of gastroesophageal reflux disease treatment with proton pump inhibitors on the risk of acute exacerbation and pneumonia in patients with COPD
por: Kang, Jieun, et al.
Publicado: (2023)

Pharmacological and Safety Profile of Dexlansoprazole: A New Proton Pump Inhibitor – Implications for Treatment of Gastroesophageal Reflux Disease in the Asia Pacific Region
por: Goh, Khean Lee, et al.
Publicado: (2016)

Time esophageal pH < 4 overestimates the prevalence of pathologic esophageal reflux in subjects with gastroesophageal reflux disease treated with proton pump inhibitors
por: Gerson, Lauren B, et al.
Publicado: (2008)

Management of laryngopharyngeal reflux with proton pump inhibitors
por: Reimer, Christina, et al.
Publicado: (2008)

Proton Pump Inhibitor-associated Mucosal Change
por: Kato, Mototsugu, et al.
Publicado: (2017)

Gastrointestinal symptoms associated with gastroesophageal reflux disease, and their relapses after treatment with proton pump inhibitors: A systematic review
por: Hosseini, Mousalreza, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_gbttjvib0isp1hsbrmgt68nsri